article
Logic-gated DARPins show targeted T-cell activation in tumours
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
List view / Grid view
Immuno-oncology
news
New organ-on-a-chip models ageing immune response for cancer vaccines
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
news
Estrone hormone linked to deadly breast cancer in obese women
A new analysis has identified the hormone estrone as a major driver of aggressive breast cancer in post-menopausal women with obesity, meaning that weight-loss drugs could help improve treatment outcomes.
news
AI powers discovery of new CBLB inhibitor ISM3830
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
news
Why TIGIT cancer therapies work in monkeys but not humans
A new study reveals that TIGIT, a key immune checkpoint targeted by cancer drugs, behaves differently in rhesus macaques and humans, suggesting current animal tests may be misleading drug development.
news
Targeting p300 may boost immunotherapy in kidney cancer
Researchers have discovered how renal medullary carcinoma cells evade immunotherapy by mimicking immune cells, driving rapid tumour progression.
news
New CAR-T cell therapy capable of destroying glioblastoma cells
A new CAR-T treatment developed in Switzerland has shown striking early success against glioblastoma, one of the deadliest brain cancers, and is now moving towards human trials.
news
FGD3 protein enhances breast cancer therapies
Scientists have identified a little-known protein, FGD3, that can boost the power of key breast cancer treatments by helping drugs rupture tumour cells and activate the immune system.
news
Sugar-coated tumours: a new target for pancreatic cancer
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves with a sugar coating. To combat this, they have developed a new antibody therapy that blocks this ‘don’t-attack’ signal, which slows tumour growth.
article
CD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
article
What’s changing in cancer drug discovery – and why it matters now
Take part in a live Q&A with oncology experts as they explore the scientific advances driving cancer drug discovery.
news
New CAR T therapy targets solid tumours safely and effectively
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
news
Senolytic drug combo boosts cancer immunotherapy and reduces side effects
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
news
Tiny models, powerful insights: how organoids are driving precision oncology
A new review has highlighted how three-dimensional organoid models are transforming cancer research by replicating the complexity of human tumours – bringing precision oncology closer to the clinic.
article
CAR T’s biggest hurdle: solving the toxicity problem
CAR T therapies are saving lives, but toxicities such as CRS and ICANS remain a major barrier. What will it take to overcome them?
